HRT Response
Hormonal Balance
Biomeme does not prescribe, supply, recommend or evaluate this therapy. This page describes which genes it acts on, not whether you should take it.
Hormone therapy acts through nuclear receptors that regulate transcription of inflammatory and metabolic genes. This page describes the genes involved and what a transcript panel can and cannot say about them.
Tracked Physiological Dimensions
On the Advanced Transcriptomics Dashboard, HRT response is tracked across three primary wellness dimensions.
Inflammation & Immune Response
Monitors the suppression of pro-inflammatory cytokines and vascular stress markers.
Metabolic Flexibility
Tracks PPARγ modulation and cellular transition between lipid and glucose metabolism.
Cellular Aging & Longevity
Measures SIRT1 chromatin remodeling activity and DNA repair pathway integrity.
Estrogenic & Progestogenic Signaling
Hormones regulate transcription by binding nuclear receptors that interact with response elements in the genome. Estrogen signaling modulates NF-κB activity and cytokine transcription. This is not a cardiovascular benefit claim: in the Women's Health Initiative, estrogen plus progestin increased coronary heart disease, stroke and pulmonary embolism, and the trial was stopped early (PMID 12117397).
This panel reports the transcription of ESR1, TNF, IL6, PPARG and SIRT1. PPARG transcript level is not a measure of insulin sensitivity or body composition.
Key Target Genes
Estrogen Receptor 1 Estrogen Signaling
Drives estrogen-mediated gene transcription, regulating lipid profiles and anti-inflammatory cascades.
Tumor Necrosis Factor & Interleukin 6 Cytokine Suppression
Pro-inflammatory cytokines. Note that on the inflammatory marker with the most pooled data, oral hormone therapy raised CRP by 37.6% across 107 randomized trials, while transdermal preparations had no effect (PMID 16918589).
Peroxisome Proliferator-Activated Receptor Gamma Adipose Distribution
Master transcriptional regulator of adipogenesis and lipid storage.
Sirtuin 1 Longevity Pathways
NAD+-dependent deacetylase. Its transcript level does not report its catalytic activity.
Scientific Citations (2)
- [1] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
- [2] Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-554.
The Biomeme Molecular Ecosystem
From deep whole-transcriptome sequencing in the laboratory to rapid point-of-care instrumentation in the field.
High-Depth RNA Sequencing
Processed at One Health Labs, Biomeme's CLIA-certified laboratory, using Illumina NovaSeq high-depth paired-end RNA sequencing. Samples are collected in venous PAXgene blood RNA tubes to stabilize cellular transcription at the moment of draw.
Biomeme/5 Handheld Platform
Beyond central-lab genomics, Biomeme engineers patented, battery-powered real-time PCR instruments. Our deployable hardware brings decentralized molecular detection directly to the field and clinical points of care.
Curious how we measure this?
Learn about the foundational science of Transcriptomics and how Biomeme brings molecular profiling to the point of need.
Ready to Learn More?
Explore how Biomeme's capabilities are being deployed across the Wellness landscape.
ABOUT THESE PANELS
Biomeme's wellness transcriptomic panels are general wellness products. They report gene activity to support a healthy lifestyle. They are not intended to diagnose, treat, cure, mitigate or prevent any disease or condition, and they are not a substitute for evaluation by a licensed healthcare professional. Results describe the state of the measured transcripts at the moment the sample was taken.